Moderna, Inc. Shareholders' Equity
Moderna, Inc. (MRNA) had Shareholders' Equity of $6.76 billion as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-07-31
- 2026-06-30: Stockholders' Equity Attributable to Parent $6.76B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $7.41B.
- 2025-12-31: Stockholders' Equity Attributable to Parent $8.65B.
- 2025-09-30: Stockholders' Equity Attributable to Parent $9.33B.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $6.76B 10-Q · filed 2026-07-31 | |
| 2026-03-31 | $7.41B 10-Q · filed 2026-07-31 | |
| 2025-12-31 | $8.65B 10-Q · filed 2026-07-31 | |
| 2025-09-30 | $9.33B 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $9.40B 10-Q · filed 2026-07-31 | |
| 2025-03-31 | $10.07B 10-Q · filed 2026-07-31 | |
| 2024-12-31 | $10.90B 10-Q · filed 2026-07-31 | |
| 2024-09-30 | $11.93B 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $11.71B 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $12.82B 10-Q · filed 2025-08-01 | |
| 2023-12-31 | $13.85B 10-K · filed 2026-02-20 | |
| 2023-09-30 | $13.46B 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $16.95B 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $18.86B 10-Q · filed 2024-08-01 | |
| 2022-12-31 | $19.12B 10-K · filed 2026-02-20 | |
| 2022-09-30 | $17.99B 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $17.98B 10-Q · filed 2023-11-03 | |
| 2022-03-31 | $17.07B 10-Q · filed 2023-08-03 | |
| 2021-12-31 | $14.14B 10-K · filed 2025-02-21 | |
| 2021-09-30 | $10.12B 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $6.70B 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $3.84B 10-Q · filed 2022-08-03 | |
| 2020-12-31 | $2.56B 10-K · filed 2024-02-23 | $2.56B 10-K · filed 2021-02-26 |
| 2020-09-30 | $2.76B 10-Q · filed 2021-11-04 | $2.76B 10-Q · filed 2020-10-30 |
| 2020-06-30 | $2.95B 10-Q · filed 2021-11-04 | $2.95B 10-Q · filed 2020-08-06 |
| 2020-03-31 | $1.64B 10-Q · filed 2021-08-05 | $1.64B 10-Q · filed 2020-05-07 |
| 2019-12-31 | $1.18B 10-K · filed 2023-02-24 | $1.17B 10-K · filed 2020-02-27 |
| 2019-09-30 | $1.25B 10-Q · filed 2020-10-30 | $1.25B 10-Q · filed 2019-11-06 |
| 2019-06-30 | $1.33B 10-Q · filed 2020-10-30 | $1.34B 10-Q · filed 2019-08-08 |
| 2019-03-31 | $1.44B 10-Q · filed 2020-08-06 | $1.45B 10-Q · filed 2019-05-09 |
| 2018-12-31 | $1.53B 10-K · filed 2022-02-25 | $1.53B 10-K · filed 2019-03-13 |
| 2018-09-30 | -$757.13M 10-Q · filed 2019-11-06 | |
| 2018-06-30 | -$688.77M 10-Q · filed 2019-11-06 | |
| 2018-03-31 | -$613.71M 10-Q · filed 2019-08-08 | |
| 2017-12-31 | -$551.37M 10-K · filed 2021-02-26 | |
| 2016-12-31 | -$334.81M 10-K · filed 2020-02-27 | |
| 2015-12-31 | -$149.76M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |